Navigation Links
Personal Genome Diagnostics Announces AACR Annual Meeting 2017 Presentations and Awards
Date:3/30/2017

BALTIMORE, March 30, 2017 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx) today announced that it has three scientific presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2017, being held April 1-5, 2017, in Washington, D.C.  The company also announced that five scientists associated with PGDx—two co-founders and three scientific advisers—are recipients of the 11th Annual AACR Team Science Award.

Doug Ward, CEO of Personal Genome Diagnostics, commented, "Our studies selected for oral presentation at the AACR Annual Meeting focus on our liquid biopsy products and technologies and our ImmunoSELECT service for the identification of tumor neoantigens for cancer immunotherapy. They demonstrate the broad leadership PGDx is committed to maintaining in the rapidly evolving cancer genomics field. We also congratulate our co-founders Dr. Luis Diaz and Dr. Victor Velculescu, along with PGDx scientific advisers Dr. Bert Vogelstein, Dr. Nickolas Papadopoulos and Dr. Kenneth Kinzler, who are among this year's recipients of the prestigious AACR Team Science Award. The talent and commitment of our people drive our success, and these individuals exemplify the excellence and teamwork that are essential to achieving great things in science."

At the AACR meeting, PGDx will present a study further validating the exceptional sensitivity and specificity of its liquid biopsy PlasmaSELECTTM 64 pan-cancer profiling assay. PGDx believes that PlasmaSELECT is the most clinically actionable, CLIA-validated pan-cancer plasma assay available today. Earlier this week, PGDx announced that PlasmaSELECT is now the first liquid biopsy profiling assay to include measurement of MSI status as a biomarker for high tumor mutational load, which makes it especially relevant for determining patient suitability for treatment with cancer immunotherapies.1

A second presentation confirms the accuracy and utility of PGDx's ImmunoSELECTTM–R service designed to identify tumor neoantigens and support development of cancer immunotherapies. The service combines the high accuracy of PGDx's CancerXomeTM analysis with its proprietary bioinformatics neoantigen prediction pipeline. The study data demonstrate that the company's combined tissue processing, macrodissection, co-extraction and neoantigen prediction methodologies provide the information needed to accurately select actionable tumor neoantigens for immuno-oncology applications.2

PGDx researchers are also participating with colleagues from Johns Hopkins University, Memorial Sloan Kettering Cancer Center and other research institutions in a late-breaking presentation focused on the detection of circulating tumor DNA in early stage cancer.

PGDx co-founders and scientific advisers Dr. Luis A. Diaz of Memorial Sloan Kettering Cancer Center and Dr. Victor Velculescu, Dr. Bert Vogelstein, Dr. Nickolas Papadopoulos and Dr. Kenneth Kinzler of Johns Hopkins University will be honored as recipients of the 11th Annual AACR Team Science Award, which will be presented at the Opening Ceremony on April 2, 2017 at 8:00 am. The AACR Team Science Award recognizes an outstanding interdisciplinary research team for its innovative and meritorious science that has advanced or likely will advance our fundamental knowledge of cancer, or a team that has applied existing knowledge to advance the detection, diagnosis, prevention or treatment of cancer. This award was established by the AACR and Eli Lilly and Co. to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer applications.

PGDx representatives will be available to discuss the company's advanced cancer genomic products and services at Booth #3022 throughout the AACR Annual Meeting. The company also is hosting an invitation-only reception Monday evening, April 3, 2017, from 6:00-9:00pm. For more information or an invitation to attend, visit the PGDx booth.

PGDx offers a complete range of cancer genome analysis tools, including exome and targeted approaches for tissue specimens, targeted approaches for plasma samples and a variety of custom tissue and plasma-based options designed to address the specific research needs of cancer researchers and drug developers. PGDx's service offerings for researchers and testing labs are complemented by the clinical services it provides through its CLIA-certified laboratory.   

1 - MS.CL10.02 - Liquid Biopsies 4,  April 4, 3:00-5:00pm, Clinical validation of a cell-free DNA liquid biopsy approach for noninvasive molecular profiling, M Nesselbush, S Angiuoli, LA Diaz, Jr., A Georgiadis, S Glynn, S Jones, L Keefer, P LoVerso, D Murphy, S Parpart-Li, D Riley, N Sengamalay, M Shukla, J Simmons, S Talati, R Steinberg, L Tucker, VE Velculescu, E Verner, A Villarta, M Sausen.

2 - PO.IM02.01 - T-cell Immunity to Cancer: New Progress, April 2, 1:00-5:00pm,  Accurate identification and prioritization of candidate neoantigens from integrated cancer exome and transcriptome sequencing of FFPE samples, M Novak, S Angiuoli, LA Diaz, Jr., A Georgiadis, S Jones, PR Loverso, S Parpart-Li, M Sevdali, VE Velculescu, EL Verner, J White, T Zhang, M Sausen. 

About Personal Genome Diagnostics  
Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome for oncology researchers, drug developers, clinicians and patients. The expert team at PGDx draws on a deep understanding of cancer biology, extensive experience in cancer genomics and clinical oncology, and the company's distinctive technologies that precisely identify and characterize unique genomic alterations in tumors. PGDx is working toward broad patient access to its genomic technologies and products, through a CLIA-certified facility providing comprehensive genomic services, as well as a portfolio of regulated tissue-based and liquid biopsy genomic testing products for laboratories worldwide. Privately-held PGDx is headquartered in Baltimore, MD. For additional information, visit PersonalGenome.com.

Contacts
PGDx Corporate:     
Melody Gretz   
973 598-5515   
mgretz@personalgenome.com              

       

Media:
Barbara Lindheim
BLL Partners LLC 
212 584-2276   
blindheim@bllbiopartners.com  

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/personal-genome-diagnostics-announces-aacr-annual-meeting-2017-presentations-and-awards-300431708.html


'/>"/>
SOURCE Personal Genome Diagnostics Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Transplanted brain cells in monkeys light up personalized therapy
2. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
3. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
4. QVC and Fashion Footwear Association of New York Invest in Personalized Breast Cancer Therapy Research
5. Lucintel’s Analysis of Growth Opportunities in Global Polymer Ingredients Used in Personal Care Industry: Market to Reach $3,495 Million by 2017
6. NYSCF scientists create personalized bone substitutes from skin cells
7. DuPont Tate & Lyle Bio Products Collaborates with RML Incorporated to Develop Bio-Based Solution for Personal Care Products
8. The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris
9. Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets
10. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
11. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
Breaking Biology Technology:
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
Breaking Biology News(10 mins):